Investors Buy Large Volume of Call Options on Boston Scientific (NYSE:BSX)

Boston Scientific Corporation (NYSE:BSX) was the target of unusually large options trading on Wednesday. Stock investors purchased 41,571 call options on the company. This is an increase of approximately 138% compared to the typical daily volume of 17,446 call options.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: CE-mark approval expands Farapulse pulsed-field ablation labeling in Europe, opening reimbursement/market access for persistent atrial fibrillation treatments and supporting procedure growth in a high-value cardiology franchise. Boston Scientific gets Farapulse label expansion in Europe
• Positive Sentiment: TD Cowen reiterated a Buy and kept a $100 price target, arguing recent share weakness presents a buying opportunity given strong organic growth and margin expansion potential. Boston Scientific: Share Price Weakness Creates Opportunity
• Positive Sentiment: Bank of America reaffirmed a Buy on BSX, noting near-term resets but citing 2027 growth drivers that support upside — a signal that institutional analysts still favor the company’s medium-term thesis. Boston Scientific: Near-Term EP Reset but 2027 Growth Drivers Support Buy Rating
• Positive Sentiment: Unusual options activity: traders bought ~41,571 call contracts (≈+138% vs. typical), indicating short-term bullish/speculative positioning that can amplify upside if positive catalysts arrive.
• Neutral Sentiment: Q4 results showed an EPS beat and ~16% revenue growth year-over-year, with FY26 guidance set (Q1 EPS 0.780–0.800; FY EPS 3.430–3.490) — solid fundamentals but not enough to offset recent sentiment-driven selling.
• Neutral Sentiment: Management presented at the TD Cowen healthcare conference; the transcript provides detail on strategy and drivers but contains no immediate surprise to change the current market narrative. Conference Presentation Transcript
• Neutral Sentiment: Market commentary pieces suggest the pullback has created a buying opportunity for long-term investors, but they also highlight the stock’s recent volatility which may keep traders cautious. Is It Time To Reconsider Boston Scientific After The Recent Share Price Pullback
• Negative Sentiment: Pomerantz LLP announced an investigation into Boston Scientific on behalf of investors, which adds legal overhang and potential litigation risk that can pressure the stock. Pomerantz Law Firm Investigation
• Negative Sentiment: Portnoy Law Firm also opened an investigation into possible securities fraud, compounding legal uncertainty and contributing to downward pressure on the share price. Portnoy Law Firm Investigation

Insider Buying and Selling

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This trade represents a 10.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Boston Scientific

Large investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in Boston Scientific by 0.8% in the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock worth $13,497,294,000 after purchasing an additional 1,115,337 shares during the last quarter. State Street Corp boosted its stake in shares of Boston Scientific by 1.1% during the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after acquiring an additional 713,379 shares during the last quarter. Synergy Asset Management LLC lifted its position in Boston Scientific by 3,493.0% during the third quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock valued at $48,297,000 after purchasing an additional 479,593 shares in the last quarter. Gladstone Institutional Advisory LLC lifted its position in shares of Boston Scientific by 39.5% during the 3rd quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider’s stock valued at $5,065,000 after buying an additional 14,700 shares in the last quarter. Finally, Channel Wealth LLC grew its stake in shares of Boston Scientific by 70.8% during the 3rd quarter. Channel Wealth LLC now owns 28,577 shares of the medical equipment provider’s stock valued at $2,790,000 after acquiring an additional 11,847 shares during the period. Institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Canaccord Genuity Group decreased their price target on Boston Scientific from $112.00 to $109.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. Robert W. Baird reduced their price objective on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. Royal Bank Of Canada dropped their target price on shares of Boston Scientific from $130.00 to $115.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Stifel Nicolaus cut their price target on shares of Boston Scientific from $125.00 to $110.00 and set a “buy” rating for the company in a report on Wednesday, February 4th. Finally, Sanford C. Bernstein reiterated an “outperform” rating and set a $112.00 price target on shares of Boston Scientific in a research report on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and an average target price of $108.36.

Boston Scientific Price Performance

Shares of BSX opened at $72.13 on Thursday. Boston Scientific has a 12-month low of $71.83 and a 12-month high of $109.50. The business has a 50-day simple moving average of $85.98 and a two-hundred day simple moving average of $94.99. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The stock has a market cap of $107.03 billion, a PE ratio of 37.18, a PEG ratio of 1.02 and a beta of 0.69.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period last year, the firm posted $0.70 earnings per share. The business’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts anticipate that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.